The synthesis and characterization of
ruthenium compounds (Ru1-Ru12) of the type [Ru(S)(2)(K)], (where S=1,10-
phenanthroline/
2,2'-bipyridine and K=itsz, MeO-btsz, 4-Cl-btsz, 2-Cl-btsz, 2-F-btsz, hfc and itsz=
isatin-3-
thiosemicarbazone, MeO-btsz=1-(4'-methoxy-benzyl)-
thiosemicarbazone, hfc=2-{[3-chloro-4-fluoro-phenylimino]methyl}
phenol, 4-Cl-btsz=1-(4'-chlorobenzyl)-
thiosemicarbazone, 2-Cl-btsz=1-(2'-chloro benzyl)-
thiosemicarbazone, 2-F-btsz=1-(2'-fluorobenzyl)-
thiosemicarbazone) are described. These
ligands form bidentate octahedral
ruthenium compounds. The title compounds were subjected to in vivo anticancer activity against a transplantable murine tumor cell line Ehrlich's
Ascites Carcinoma (EAC) and in vitro cytotoxic activity against human
cancer cell line Molt 4/C8, CEM and murine tumor cell line L1210.
Ruthenium compounds (Ru1-Ru12) showed promising
biological activity especially in decreasing
tumor volume and viable
ascites cell counts. Treatment with these compounds prolonged the life span of mice bearing EAC
tumor by 10-43%. In vitro evaluation of these
ruthenium compounds revealed cytotoxic activity from 0.24 to 27 microM against Molt 4/C8, 0.27 to 48 microM against CEM, and 0.94 to 248 microM against L1210. Their
ligands alone failed to show cytotoxic activity at the concentrations tested (68-405 microM).